Information on this web-page is provided to investigators as part of the FDA-IDE tDCS-LTE trials. tDCS has been approved in several countries for depression and pain treatment.
Current or prospective clinical tDCS-LTE Depression sites should contact Soterix Medical at contact@SoterixMedical.com
SNAPpad™ electrodes are optimized for tDCS reliability using rivet-control of current edge buildup and advanced sponge materials for consistent skin contact. SNAPpad™ electrodes are the easy to use, even in home-settings, coming fully assembled and saturated with a single snap connector.
Single-use means no hassle or concerns about cleaning electrodes.
Soterix Medical’s exclusive Limited Total Energy (LTE) output management software automatically adjusts delivered current to avoid aborted sessions and to minimize power.4 This provides unparalleled reliability and tolerability, even in home-settings.(2,3)
Soterix medical unique technology (including LTE) has been validated in the largest and most compressive clinical trials (complete Soterix Medical device trials). This includes the ELECT-tDCS depression trials published in the New England Journal of Medicine5 that leveraged tDCS-LTE™ devices and the OLE snap-strap for optimized DLPFC stimulation. Soterix Medical tDCS technology is the most widely used stimulation solution on the market.
Soterix Medical REMOTE Neuromodulation is the only system with device, accessories, and software designed for deployed use7. Safe transcranial Electrical Stimulation requires advanced systems designed for consistency and control. REMOTE Neuromodulation is the only system designed from the ground up to allow translation of clinical tES, including tDCS protocols, to diverse deployed environments, while maintaining medical standards.8